Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 12/1/06 → 12/30/15 |
Financiación
- Bavarian Nordic: 64.495,00 US$
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA-BN (IMVAMUNE) Smallpox Vaccine in 18-40 Year Old Subjects wth Diagnosed Atopic Dermatitis
- Greenberg, Richard (PI)